Tag Archives: BEIR

Long Island Bioscience Hub Selects Third Bioentrepreneur-In-Residence

Posted on by

Entrepreneur Derek Brand Selected to Facilitate New Bioscience Ventures

STONY BROOK, N.Y. – December 14, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Derek Brand as BioEntrepreneur-In-Residence (B-EIR) for the Long Island Bioscience Hub.  The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions.

Mr. Brand most recently served as Vice President of Business Development at Enumeral Biomedical Corp., which licensed a single cell immunology platform out of MIT and is now a publicly traded biotechnology company with a pipeline of novel immunotherapies in oncology.  In addition to Enumeral, Mr. Brand has held both business and scientific roles at multiple early-stage, venture-backed biomedical startup companies; he has also held commercial leadership roles at GE and the New York Academy of Sciences and presently serves on the advisory board of Allovate LLC, a novel allergy immunotherapy company in NYC. He received his MBA from Babson College and his B.A. in biology from Hamilton College.

“I’m excited to take on the role of BioEntrepreneur-in-Residence and looking forward to bringing a diverse array of startup experience to the LIBH community” Mr. Brand stated. “The opportunity to dig in at the earliest stages of innovation with the exceptional scientists at Long Island institutions is a terrific opportunity, and it’s an honor to have been selected.”

“Mr. Brand is an excellent addition to the team of entrepreneurs engaged in the B-EIR initiative” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “We are excited to see the positive impact these entrepreneurs will have as new companies are launched within the Hub.”

Mr. Brand joins an impressive roster of seven B-EIRs that was expanded in November to include Drs. Brian McCarthy and Gian Luca Araldi. Dr. McCarthy has an extensive background as an investment analyst and as the President and CEO of the startup Influmedix while Dr. Araldi has had a distinguished career in drug discovery within the pharmaceutical industry and as the Founder and Principal of US Pharma Services.

LIBH B-EIRs are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation.  B-EIRs will have the support of the LIBH business and technology development staff, along with external industry advisors to develop successful commercialization strategies, and position the company for SBIR/STTR grant opportunities, and Angel and VC investment. The LIBH can also provide opportunities to access development funding to help advance technologies towards commercialization.  Ultimately, the goal is to foster the creation and growth of new ventures that leverage the exceptional scientific and technological advances taking place at LIBH institutions.

Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence

Posted on by
Reply

Biotechnology Strategist Brian McCarthy and Pharma Executive Gian Luca Araldi
selected to launch new bioscience companies

STONY BROOK, N.Y. – November 23, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Brian McCarthy, PhD and Gian Luca Araldi, PhD, as BioEntrepreneurs-In-Residence (B-EIR) for the Long Island Bioscience Hub.  The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions.

Drs. McCarthy and Araldi have broad bioscience industry experience and comprehensive knowledge of commercializing academic technologies. In their roles as BEIR they will identify technologies that have the potential to support company formation in the region.  Each brings unique skills and perspectives to technology assessment and bioscience-startups.

Dr. McCarthy is a senior biotechnology strategist with operational, start-up, development, and financial expertise. He currently serves as a business advisor to Gismo Therapeutics Inc. and VP of Business and Clinical Development at Viatar CTC Solutions Inc. Prior to his Wall Street and entrepreneurial career, Dr. McCarthy was a faculty member at Cornell University Medical College and the National Naval Medical Center. Dr. McCarthy received his PhD in Neurobiology from Stony Brook University.

Dr. Araldi is a pharmaceutical and biotechnology executive with more than 25 years of experience ranging from basic research through clinical development at major pharmaceutical companies including Glaxo, Forest Laboratories and Merck-Serono.  Dr. Araldi has been involved in the development of key medicines such as Teflaro®, Dutogliptin®, Gavestinel®, Sanfetrinem® and Sanfetrinem® Cilexetil and is the inventor of 113 granted patents. Dr. Araldi received doctorate degrees in Organic Chemistry and Pharmacy from the University of Parma (Italy) and recently received his M.B.A. in Finance from Long Island University Post.

“The Long Island Bioscience Hub is excited to announce the appointments of Drs. McCarthy and Araldi as BioEntrepreneurs-in-Residence” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “They join a talented roster of five existing BioEntrepreneurs in Residence at the Center for Biotechnology who are well on their way to commercializing technologies and building their companies.”

As B-EIRs Drs. McCarthy and Araldi are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation.  They will have the support of the LIBH business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. The LIBH can also provide access to a competitive pool of technology development funding to help move their technologies down a commercial pathway.  Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment.

Traverse Biosciences Announces Issuance of U.S. Patent

Posted on by
Reply

Traverse Biosciences has announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,187,406 entitled, “Curcumin Analogues as Zinc Chelators and Their Uses,” which the company has exclusively licensed from the Research Foundation for the State University of New York (RF/SUNY). The issued patent includes claims that cover the composition of matter of the company’s proprietary library of chemically-modified curcumins, including its lead drug candidate, TRB-N0224.
Read more on the Traverse Biosciences website.

 

Long Island Bioscience Hub is seeking experienced BioEntrepreneurs-in Residence

Posted on by
Reply

The Long Island Bioscience Hub (LIBH) is seeking experienced BioEntrepreneurs-in Residence (BEIRs) to launch new bioscience ventures in the Long Island, New York region. Company formation will be based upon commercially promising biomedical technologies emerging from Stony Brook University (SBU), Cold Spring Harbor Laboratory and Brookhaven National Laboratory.

To help facilitate this process, the LIBH will provide:

  • modest retainer/milestone payments to BEIRs for a predetermined period of time
  • access to technology development funding on a competitive basis
  • senior staff support to assist with commercialization strategies
  • office space
  • access to experienced industry advisors
  • introductions to investors and professional services

BEIRs will also have access to the resources of the LIBH including: faculty expertise, core research and engineering facilities, libraries, business incubators, the 245-acre Research Park, and a suite of end-to-end economic development programs. BEIRs will be responsible for evaluation of biomedical technologies available for license from LIBH partner institutions. BEIRs will ultimately select specific technologies to form the basis of a company, and will be required to develop detailed commercialization strategies, business plans and investor presentations. BEIRs will negotiate and execute option and/or license agreements with LIBH partner institutions as may be appropriate, secure capital from both public and private sources, and exit the BEIR program to lead the Long Island- based company as CEO. BEIRs will also provide guidance to entrepreneurial faculty members and participate in technology reviews and other meetings as deemed appropriate.

The most compelling BEIR candidate(s) will possess domain expertise and technical proficiency in the life sciences or engineering, as well as business acumen and industry experience, particularly in early stage technology commercialization, new venture creation, and fundraising. Advanced degree in life sciences, engineering, business and/or law are preferred. Terms of engagement dependent upon individual circumstances. BEIRs will report to the Center for Biotechnology Advisory Board.

Interested parties should contact to Eleanor Allen, with a statement of interest and resume. Inquiries will be considered on a rolling basis until appropriate candidates are identified.

The LIBH, was established by the Center for Biotechnology (CFB), a New York State Center for Advanced Technology, in collaboration with Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, and with additional support provided by the National Institutes of Health REACH initiative (Research Evaluation And Commercialization Hub), Research Foundation for SUNY, and Empire State Development. The LIBH will foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

Center for Biotech Receives NIH Award to Develop a Bioscience Hub

Posted on by
Reply

STONY BROOK, N.Y., April 8, 2015 The National Institutes of Health (NIH) has granted Stony Brook University’s Center for Biotechnology a three-year $3 million award through the SUNY Research Foundation to establish the Long Island Bioscience Hub (LIBH). The award is part of the NIH’s Research Evaluation and Commercialization Hub (REACH) program and one of only three granted nationwide.The hub will be a collaboration between Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory and is designed to help accelerate the translation of biomedical discoveries into new drugs, devices, and diagnostics to improve patient care and enhance health.

Stony Brook’s Center for Biotechnology will lead the efforts of the LIBH, coordinating its comprehensive technology commercialization efforts across the three partner institutions. Such activities include technology development programs, establishing strategic partnerships, recruiting experienced entrepreneurs to provided experienced company management, and providing services such as education and mentoring that will help faculty innovators move their academic innovations into the commercial sector via a start-up company, licensing opportunity, and/or a strategic partnership.

The Long Island Bioscience Hub will build upon Stony Brook’s existing strengths in translational research and commercialization to develop an infrastructure across partner institutions, which will accelerate the yield of new healthcare innovations, said Samuel Stanley Jr., MD, President of Stony Brook University. This partnership will advance New York State’s ever-expanding bio-based entrepreneurial ecosystem with new discoveries that fuel new company formation and jobs in biotechnology.

With this award, the NIH recognized the great potential for translational research and technology development that resides in our region, says Clinton T. Rubin, PhD, Principal Investigator, Distinguished Professor, Chair of the Department Biomedical Engineering, and Director of the Center for Biotechnology. We’re looking forward to the opportunity to enhance what is already a bourgeoning innovation economy and entrepreneurial ecosystem.

The REACH program is based on the NIH Center for Advanced Innovations (NCAI) initiative created the National Heart, Lung and Blood Institute (NHLBI). The three hubs established under the REACH program will work collaboratively with the NCAIs to develop best practices and share resources where appropriate. REACHs will also be able to take advantage of unique partnerships with the U.S. Food and Drug Administration, the United States Patent Office, and the Center for Medicare & Medicade Services.

Each NIH REACH hub will provide funding for feasibility studies and coordinate access to expertise in areas required for early stage technology development, including scientific, regulatory, business, legal, and project management. Skill development and providing hands-on experience in entrepreneurism are also aims of the hubs.

The Greatest Hits How Success Breeds Success

Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory have a demonstrated capacity for bioscience innovation that has advanced the course of biomedical science and contributed to improved healthcare through FDA approved therapies including ReoPro&reg, SAFHS, Xiaflex&reg, Periostat® and Oracea&reg, new medical devices including 3Dvirtual colonoscopy and LivMD$reg, and new company formation including New England BioLabs, OSI Pharmaceuticals, Collagenex, Pharmacopeia, and Exogen.